NovaBridge Biosciences stock gains 10.38 percent on Nasdaq

Published on 10/20/2026 at 18:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 12, 2026. NovaBridge Biosciences stock costs USD 1.44 on October 20, 2026 at 12:38 p.m. ET, up 10.38 percent on Nasdaq.

Price and earnings dates

NovaBridge Biosciences stock gained 10.38 percent on October 20, 2026.
Barron's lists a third-quarter 2026 earnings estimate of minus USD 0.18 per share.
NovaBridge Biosciences stock costs USD 1.44 on Nasdaq on October 20, 2026 at 12:38 p.m. ET.

NBP, US44975P1030, Illustration mit AI erstellt.

NovaBridge Biosciences (ISIN US44975P1030) was trading at USD 1.44 on Nasdaq on October 20, 2026 at 12:38 p.m. ET, up 10.38 percent from the prior session close of USD 1.30. Barron's lists November 12, 2026 as the expected date for the company's third-quarter results.

November date sets next checkpoint

The November report is the next scheduled event for the clinical-stage biotechnology company. Its current pipeline centers on oncology programs including givastomig, ragistomig and uliledlimab, while its ophthalmology business is developing VIS-101, according to NovaBridge Biosciences.

Nasdaq move sharpens price picture

The intraday range ran from USD 1.30 to USD 1.44 on October 20, 2026, while the 52-week range stood at USD 1.26 to USD 5.33. The current market value was USD 165.4 million, and trading volume reached 411,591 shares by 12:38 p.m. ET.

Analyst estimates remain negative

Barron's lists a consensus estimate of minus USD 0.18 in earnings per share for the third quarter of 2026. The same page shows an average target of USD 9.00 from two ratings, alongside the scheduled November reporting date.

Stock remains in clinical development

NovaBridge's investment case remains tied to clinical progress rather than current product revenue. The company describes itself as a clinical-stage biopharmaceutical business focused on medicines for areas of significant unmet need, with oncology and ophthalmology as its principal research areas.

Nasdaq quote at midday

On Nasdaq, NovaBridge Biosciences was trading at USD 1.44 on October 20, 2026 at 12:38 p.m. ET, up 10.38 percent from the prior session close of USD 1.30.